[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
April 27, 2011

Implementation of Evidence-Based Therapies for Myocardial Infarction and Survival

Author Affiliations

Author Affiliations: Division of Cardiovascular Medicine, Texas Tech University Health Sciences Center, El Paso, Texas.

JAMA. 2011;305(16):1710-1711. doi:10.1001/jama.2011.521

Cardiovascular disease remains the most common cause of morbidity and mortality in the United States, and each year an estimated 785 000 US residents will have a new myocardial infarction (MI), and approximately 470 000 will have a recurrent MI.1 ST-segment elevation myocardial infarction (STEMI) constitutes a subset of MI presentation, defined by characteristic symptoms of myocardial ischemia and associated with ST-segment elevation or new or presumed new left bundle-branch block. Among patients presenting with an MI, the percentage of cases with STEMI varies in different registries and databases. According to the National Registry of Myocardial Infarction 4 (NRMI-4), among all patients with MI, approximately 29% present with STEMI.2

First Page Preview View Large
First page PDF preview
First page PDF preview